论文部分内容阅读
他汀药除具有强效降脂作用外,尚兼有抗血小板黏附聚集等效用。既往亦曾有报道称,他汀药可降低特发性静脉血栓栓塞(VTE)风险。然而迄今关于他汀药与肺梗死(PE)复发风险间关系远不清楚,现就其进行大样本调研分析。受检对象为3 093例因首发PE而住院患者,平均基线年龄(61.3±17.0)岁。研究中均于出院前服用了维生素K拮抗剂(VKA),另有737例于出院前或随访继后服用了他汀药,为用药组;余2 356例系素未使用他汀药的未用药组。且使用VKA人均约199 d。而使用他汀药者人均1 557 d。人均用药
In addition to a strong statin lipid-lowering effect, but also both anti-platelet aggregation and the equivalent effect. It has also been previously reported that statins reduce the risk of idiopathic venous thromboembolism (VTE). However, so far the relationship between statin and the risk of recurrent pulmonary infarction (PE) is far from clear and large sample studies are being conducted. The subjects were 3 093 hospitalized patients with PE, with an average baseline age of (61.3 ± 17.0) years. In the study, vitamin K antagonists (VKA) were taken before discharge and another 737 patients were taken statins before discharge or follow-up. The remaining 2 356 untreated patients who did not use statin . And using VKA per capita about 199 d. The average per capita use of statins 1 557 d. Per capita medication